Advertisement

Lymphomas of the Ocular Adnexa

  • Wajiha Kheir
  • Sudip Thakar
  • Bita Esmaeli
Chapter

Abstract

Lymphoid tumors are the most common primary orbital tumors. The majority of ocular adnexal lymphomas (OAL) are low grade. In order of frequency, the most common histologic subtypes of lymphoma in the orbit and ocular adnexa are marginal zone lymphoma (“MALT”), follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The American Joint Committee on Cancer (AJCC) classification for ocular adnexal lymphoma is more detailed in terms of the extent of involvement of the orbital and ocular structures, while the Ann Arbor staging may be more relevant to systemic staging of lymphoma. The role of positron emission tomography (PET)/computed tomography (CT) scans and bone marrow biopsy in staging of ocular adnexal lymphoma are better defined. Treatment options depend on the stage of lymphoma and the histologic subtype of lymphoma. Treatments that may include very low-dose radiation therapy, monoclonal antibody treatment, radioimmunotherapy, and systemic chemotherapy may be considered depending on the stage and histologic subtype of OAL.

Keywords

Ocular adnexal lymphoma Orbital lymphoma Extranodal marginal zone lymphoma Radiation therapy 

References

  1. 1.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84(5):1361.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Rasmussen PK, Ralfkiaer E, Prause JU, Sjö LD, Specht L, Rossing HH, et al. Follicular lymphoma of the ocular adnexal region: a nation-based study. Acta Ophthalmol. 2015;93(2):184–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Munch-Petersen HD, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. JAMA Ophthalmol. 2015;133(2):165–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Stagner AM, Jakobiec FA, Freitag SK. Primary cutaneous extranodal marginal zone B-cell lymphoma of the eyelid skin: diagnostic clues and distinction from other ocular adnexal diseases. Surv Ophthalmol. 2016;61(3):333–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Kirkegaard MM, Coupland SE, Prause JU, Heegaard S. Malignant lymphoma of the conjunctiva. Surv Ophthalmol. 2015;60(5):444–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Kirkegaard MM, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Conjunctival lymphoma—an international multicenter retrospective study. JAMA Ophthalmol. 2016;134(4):406–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Shields CL, Shields JA, Eagle RC. Rapidly progressive T-cell lymphoma of the conjunctiva. Arch Ophthalmol. 2002;120(4):508–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Rasmussen P, Ralfkiaer E, Prause JU, Sjö LD, Siersma VD, Heegaard S. Malignant lymphoma of the lacrimal gland: a nation-based study. Arch Ophthalmol. 2011;129(10):1275–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Oh D-E, Kim Y-D. Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol. 2007;125(12):1668–73.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen Y-J, Chen J-T, Lu D-W, Gao H-W, Tai M-C. Primary peripheral T-cell lymphoma of the orbit. Arch Ophthalmol. 2009;127(8):1070–2.CrossRefPubMedGoogle Scholar
  12. 12.
    Coupland SE, Krause L, Delecluse H-J, Anagnostopoulos I, Foss H-D, Hummel M, et al. Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. Ophthalmology. 1998;105(8):1430–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol. 2007;125(12):1663–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 montgomery lecture, part 1. Ophthalmology. 2004;111(5):997–1008.CrossRefPubMedGoogle Scholar
  15. 15.
    Shinder R, Al-Zubidi N, Esmaeli B. Survey of orbital tumors at a comprehensive cancer center in the United States. Head Neck. 2011;33(5):610–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Demirci H, Shields CL, Shields JA, Honavar SG, Mercado GJ, Tovilla JC. Orbital tumors in the older adult population. Ophthalmology. 2002;109(2):243–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Hassan WM, Alfaar AS, Bakry MS, Ezzat S. Orbital tumors in USA: difference in survival patterns. Cancer Epidemiol. 2014;38(5):515–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Lukes R, Collins R. New approaches to the classification of the lymphomata. Br J Cancer Suppl. 1975;2:1.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Rappaport H. Classification of neoplastic diseases of the reticular system. In: The lymphoreticular tumours in Africa/les tumeurs lymphoréticulaires en Afrique. Basel: Karger Publishers; 1964. p. 394–409.Google Scholar
  20. 20.
    Robb-Smith A. US National Cancer Institute working formulation of non-Hodgkin’s lymphomas for clinical use. Lancet. 1982;320(8295):432–4.CrossRefGoogle Scholar
  21. 21.
    Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Demirci H, Shields CL, Karatza EC, Shields JA. Orbital lymphoproliferative tumors: analysis of clinical features and systemic involvement in 160 cases. Ophthalmology. 2008;115(9):1626–31. e1623CrossRefPubMedGoogle Scholar
  23. 23.
    Lazzarino M, Morra E, Brusamolino E, Pagnucco G, Bernasconi C, Rosso R, et al. Clinicopathologic and immunologic characteristics of non-Hodgkin’s lymphomas presenting in the orbit. A report of eight cases. Cancer. 1985;55(9):1907–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Woog JJ, Kim YD, Yeatts RP, Kim S, Esmaeli B, Kikkawa D, et al. Natural killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology. 2006;113(1):140–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Marchino T, Ibáñez N, Prieto S, Novelli S, Szafranska J, Mozos A, et al. An aggressive primary orbital natural killer/T-cell lymphoma case: poor response to chemotherapy. Ophthalmic Plast Reconstr Surg. 2014;30(5):e131–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Cruz AA, Valera FC, Carenzi L, Chahud F, Barros GE, Elias J Jr. Orbital and central nervous system extension of nasal natural killer/T-cell lymphoma. Ophthalmic Plast Reconstr Surg. 2014;30(1):20–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Janatpour KA, Choo PH, Lloyd WC. Primary orbital peripheral T-cell lymphoma: histologic, immunophenotypic, and genotypic features. Arch Ophthalmol. 2007;125(9):1289–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Esmaeli B, Ahmadi MA, Manning J, McLaughlin PW, Ginsberg L. Clinical presentation and treatment of secondary orbital lymphoma. Ophthalmic Plast Reconstr Surg. 2002;18(4):247–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Droll L, Savar A, Esmaeli B. Eyelid and conjunctival neoplasms. In: Smith and Nesi’s ophthalmic plastic and reconstructive surgery. New York: Springer; 2012. p. 535–50.CrossRefGoogle Scholar
  30. 30.
    Nutting C, Shah-Desai S, Rose G, Norton A, Plowman P. Thyroid orbitopathy possibly predisposes to late-onset of periocular lymphoma. Eye. 2006;20(6):645–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol. 2003;40(2):124–32.CrossRefPubMedGoogle Scholar
  32. 32.
    Matthews JM, Moreno LI, Dennis J, Byrne GE, Ruiz P, Dubovy SR, et al. Ocular adnexal lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis. Br J Haematol. 2008;142(2):246–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Blasi MA, Tiberti AC, Valente P, Laguardia M, Sammarco MG, Balestrazzi A, et al. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. Ophthalmology. 2012;119(3):494–500.CrossRefPubMedGoogle Scholar
  34. 34.
    Verma V, Shen D, Sieving PC, Chan C-C. The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol. 2008;53(4):312–31.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sjö NC, Foegh P, Juhl BR, Nilsson H-O, Prause JU, Ralfkiaer E, et al. Role of Helicobacter pylori in conjunctival mucosa-associated lymphoid tissue lymphoma. Ophthalmology. 2007;114(1):182–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Lee S-B, Yang J-W, Kim C-S. The association between conjunctival malt lymphoma and Helicobacter pylori. Br J Ophthalmol. 2008;92(4):534–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B. Meta–analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer. 2007;110(4):809–15.CrossRefPubMedGoogle Scholar
  38. 38.
    Rosado MF, Byrne GE, Ding F, Fields KA, Ruiz P, Dubovy SR, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006;107(2):467–72.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell’Oro S, Fleischhauer K, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586–94.CrossRefPubMedGoogle Scholar
  40. 40.
    Kiesewetter B, Lukas J, Kuchar A, Mayerhoefer ME, Streubel B, Lagler H, et al. Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (malt) lymphoma of the ocular adnexa: single center experience of 60 patients. PLoS One. 2014;9(7):e104004.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gerbino G, Boffano P, Benech R, Baietto F, Gallesio C, Arcuri F, et al. Orbital lymphomas: clinical and radiological features. J Cranio-Maxillofac Surg. 2014;42(5):508–12.CrossRefGoogle Scholar
  42. 42.
    Rasmussen PK, Coupland SE, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, et al. Ocular adnexal follicular lymphoma: a multicenter international study. JAMA Ophthalmol. 2014;132(7):851–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Shields CL, Shields JA, Carvalho C, Rundle P, Smith AF. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108(5):979–84.CrossRefPubMedGoogle Scholar
  44. 44.
    Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood. 2009;114(3):501–10.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Shazly TA, Mitchell EB, Bonhomme GR, Schuman JS. Lymphoma of the orbit masquerading as Tolosa-Hunt syndrome. BMC Ophthalmol. 2015;15(1):1.CrossRefGoogle Scholar
  46. 46.
    Dias JSFM, Dittrich MAR, Sousa JMD, Teixeira LF, Manso PG. Medial rectus muscle myositis as an atypical presentation of mucosa-associated lymphatic tissue lymphoma: a case report. Arq Bras Oftalmol. 2014;77(2):116–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Radhakrishnan S, Maneksha V, Adulkar N. Crystal-storing histiocytosis masquerading ocular adnexal lymphoma: a case report and review of literature. Ophthalmic Plast Reconstr Surg. 2014;30(3):e67–9.PubMedGoogle Scholar
  48. 48.
    Smedby KE, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood. 2008;111(8):4029–38.CrossRefGoogle Scholar
  49. 49.
    Cunningham ET Jr, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med. 1998;339(4):236–44.CrossRefPubMedGoogle Scholar
  50. 50.
    Reifler DM, Warzynski MJ, Blount WR, Graham DM, Mills KA. Orbital lymphoma associated with acquired immune deficiency syndrome (AIDS). Surv Ophthalmol. 1994;38(4):371–80.CrossRefPubMedGoogle Scholar
  51. 51.
    Yun S, Ko J, Vincelette ND, Anwer F. Lymphomatous orbital infiltration and vision loss in diffuse large B-cell lymphoma. BMJ Case Rep. 2014;2014:bcr2014204613.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Esmaeli B, Sniegowski M. Orbital and ocular adnexal lymphoma. Orbital tumors. New York: Springer; 2015. p. 145–53.Google Scholar
  53. 53.
    Politi LS, Forghani R, Godi C, Resti AG, Ponzoni M, Bianchi S, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring 1. Radiology. 2010;256(2):565–74.CrossRefPubMedGoogle Scholar
  54. 54.
    Sullivan T, Valenzuela A. Imaging features of ocular adnexal lymphoproliferative disease. Eye. 2006;20(10):1189–95.CrossRefPubMedGoogle Scholar
  55. 55.
    Prat MC, Surapaneni K, Chalian H, DeLaPaz RL, Kazim M. Ocular adnexal lymphoma: monitoring response to therapy with diffusion-weighted imaging. Ophthalmic Plast Reconstr Surg. 2013;29(6):424–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, et al. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2014;55(5):1013–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkin’s disease. Radiol Clin N Am. 2007;45(4):697–709.CrossRefPubMedGoogle Scholar
  58. 58.
    Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease 1. Radiographics. 2010;30(1):269–91.CrossRefPubMedGoogle Scholar
  59. 59.
    Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 2006;113(12):2331–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging Retina. 2007;38(4):319–25.Google Scholar
  61. 61.
    Roe RH, Finger PT, Kurli M, Tena LB, Iacob CE. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology. 2006;113(10):1854–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Thuro BA, Ning J, Peng AS, Pace ST, Dudeja G, Ozgur O, et al. Rates of positive findings on positron emission tomography and bone marrow biopsy in patients with ocular adnexal lymphoma. Ophthal Plast Reconstr Surg. 2016;33(5):355–60.CrossRefGoogle Scholar
  63. 63.
    Eagle RC. Eye pathology: an atlas and text. Philadelphia: Lippincott Williams & Wilkins; 2012.Google Scholar
  64. 64.
    Albert DM, Jakobiec FA. Principles and practice of ophthalmology. Philadelphia: WB Saunders Company; 2000.Google Scholar
  65. 65.
    Suga K, Yasuhiko K, Hiyama A, Takeda K, Matsunaga N. F-18 FDG PET/CT findings in a patient with bilateral orbital and gastric mucosa-associated lymphoid tissue lymphomas. Clin Nucl Med. 2009;34(9):589–93.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Ilica AT, Kocacelebi K, Savas R, Ayan A. Imaging of extranodal lymphoma with PET/CT. Clin Nucl Med. 2011;36(10):e127–38.CrossRefPubMedGoogle Scholar
  67. 67.
    Rath S, Connors JM, Dolman PJ, Rootman J, Rootman DB, White VA. Comparison of American Joint Committee on Cancer TNM-based staging system and ann arbor classification for predicting outcome in ocular adnexal lymphoma. Orbit. 2014;33(1):23–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Sniegowski MC, Roberts D, Bakhoum M, Mc Laughlin P, Yin VT, Turturro F, et al. Ocular adnexal lymphoma: validation of American Joint Committee on Cancer Seventh Edition Staging Guidelines. Br J Ophthalmol. 2014;2014:bjophthalmol-2013-304847.Google Scholar
  69. 69.
    Lee SE, Paik JS, Cho WK, Choi BO, Lee SN, Jung SE, et al. Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (malt lymphoma). Am J Hematol. 2011;86(3):262–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Aronow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD. Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. Ophthalmology. 2013;120(9):1915–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Kennerdell JS, Flores NE, Hartsock RJ. Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa. Ophthalmic Plast Reconstr Surg. 1999;15(2):129–33.CrossRefPubMedGoogle Scholar
  72. 72.
    Harada K, Murakami N, Kitaguchi M, Sekii S, Takahashi K, Yoshio K, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys. 2014;88(3):650–4.CrossRefPubMedGoogle Scholar
  73. 73.
    Parikh RR, Moskowitz BK, Maher E, Della Rocca D, Della Rocca R, Culliney B, et al. Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy. Leuk Lymphoma. 2015;56(5):1266–70.CrossRefPubMedGoogle Scholar
  74. 74.
    Teckie S, Qi S, Lovie S, Navarrett S, Hsu M, Noy A, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92(1):130–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Woolf D, Kuhan H, Shoffren O, Akinnawo E, Sivagurunathan B, Boyce H, et al. Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy. Clin Oncol. 2015;27(3):153–9.CrossRefGoogle Scholar
  76. 76.
    Fasola CE, Jones JC, Huang DD, Le Q-T, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 gy× 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86(5):930–5.CrossRefPubMedGoogle Scholar
  77. 77.
    Ferreri A, Ponzoni M, Martinelli G, Muti G, Guidoboni M, Dolcetti R, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica. 2005;90(11):1578–9.PubMedGoogle Scholar
  78. 78.
    Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, et al. Prospective trial of targeted radioimmunotherapy with y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20(4):709–14.CrossRefPubMedGoogle Scholar
  79. 79.
    Tuncer S, Tanyıldız B, Basaran M, Buyukbabani N, Dogan O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res. 2015;40(8):780–5.CrossRefPubMedGoogle Scholar
  80. 80.
    Esmaeli B, Murray JL, Ahmadi MA, Naderi A, Singh S, Romaguera J, et al. Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol. 2002;120(9):1225–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Shome D, Esmaeli B. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa. Curr Opin Ophthalmol. 2008;19(5):414–21.CrossRefPubMedGoogle Scholar
  82. 82.
    Song E-K, Kim S-Y, Kim T, Lee K-W, Yun T, Na I-I, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol. 2007;19(2):242–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal malt lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375–82.CrossRefPubMedGoogle Scholar
  84. 84.
    Grünberger B, Hauff W, Lukas J, Wöhrer S, Zielinski C, Streubel B, et al. ‘Blind’ antibiotic treatment targeting chlamydia is not effective in patients with malt lymphoma of the ocular adnexa. Ann Oncol. 2006;17(3):484–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Savino G, Battendieri R, Gari M, Caputo CG, Laurenti L, Blasi MA. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. J Cancer Res Clin Oncol. 2013;139(7):1251–5.CrossRefPubMedGoogle Scholar
  86. 86.
    Kinoshita S, Kase S, Ando R, Dong Z, Fukuhara J, Dong Y, et al. Expression of vascular endothelial growth factor in human ocular adnexal lymphoma. Invest Ophthalmol Vis Sci. 2014;55(6):3461–7.CrossRefPubMedGoogle Scholar
  87. 87.
    Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim S, et al. Long-term follow-up results of no initial therapy for ocular adnexal malt lymphoma. Ann Oncol. 2006;17(1):135–40.CrossRefPubMedGoogle Scholar
  88. 88.
    Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17):2902–13.CrossRefPubMedGoogle Scholar
  89. 89.
    Goodlad J, MacPherson S, Jackson R, Batstone P, White J. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology. 2004;44(3):268–76.CrossRefPubMedGoogle Scholar
  90. 90.
    Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, et al. Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Am J Surg Pathol. 2009;33(4):591.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyAmerican University of Beirut Medical CenterBeirutLebanon
  2. 2.Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations